News

Semaglutide, an anti-diabetic medication, did not slow Alzheimer’s disease progression in two large, placebo-controlled Phase 3 clinical trials sponsored by its developer, Novo Nordisk. As a result, the planned one-year extension period for both will be stopped. The EVOKE (NCT04777396) and…

Health Canada has conditionally approved Leqembi (lecanemab) for certain adults with early Alzheimer’s disease, making it the first treatment approved in Canada that targets an underlying cause of early Alzheimer’s by removing toxic amyloid-beta proteins from the brain. The therapy, co-developed by Eisai and Biogen, was cleared for…

The European Commission has approved Eli Lilly‘s monthly infusion therapy Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease. The treatment targets sticky protein clumps, or amyloid plaques, in the brain and is specifically indicated for people in the early stages of the disease who meet specific…

The U.S. Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb), an under-the-skin autoinjector formulation for maintenance dosing in early Alzheimer’s disease. The approval, announced by co-developers Biogen and Eisai, applies to those who first receive at least 1.5 years of the intravenous version. The approval…

September is World Alzheimer’s Month, and the global Alzheimer’s disease community is looking to raise awareness and combat stigma related to Alzheimer’s and other forms of dementia. “This September, we are … advocating for greater awareness and understanding around dementia in a direct campaign that encourages people to ask…

An experimental oral therapy called blarcamesine appears to slow the progression of Alzheimer’s disease, reducing the rate of cognitive decline and preserving daily function over the long term, according to new trial data from its developer, Anavex Life Sciences. The data “indicate disease-modifying effect of oral blarcamesine and…

The U.S. Food and Drug Administration (FDA) has approved a more gradual titration dosing schedule for Kisunla (donanemab) for people with early symptomatic Alzheimer’s disease based on evidence that it can lower the risk of ARIA-E, a potentially serious side effect characterized by brain swelling. While the total…

June is Alzheimer’s and Brain Awareness Month, and the Alzheimer’s Association is urging patients, caregivers, and supporters to “take action now — for yourself, your loved ones, and for the fight to end Alzheimer’s.” The U.S.-based nonprofit is taking to social media and hosting both virtual and in-person events…

A new patient advocacy organization, the ApoE4 Alzheimer’s Alliance, has launched in the U.S., with a goal of helping advance both supportive policies and the development of treatments for people with Alzheimer’s disease associated with the ApoE4 gene variant. According to the National Institutes of Health, this variant…

Leqembi (lecanemab) has won marketing authorization in the European Union for the treatment of certain adults with early Alzheimer’s disease, making it the first therapy that targets an underlying cause of the neurodegenerative condition to be approved in the region. The treatment is indicated for adults with mild…